Scott Kopetz: TAS-102 in ctDNA-Defined MRD After Adjuvant Therapy in Colorectal Cancer
Scott Kopetz, Associate Vice President for Translational Integration at MD Anderson Cancer Center, shared a post on LinkedIn he and colleagues co-authored published in Journal of Clinical Oncology.
“Phase II INTERCEPT-TT: TAS-102 cleared ctDNA in 5/15 (33%) CRC patients with MRD at 6mo, vs 2/30 (7%) in controls, and prolonged median DFS to 9.4mo vs 5.8mo.
Questions remain on durability.
This is a setting where we should be shooting for cures if possible, and ALTAIR randomized study suggests we may not be getting these. Ongoing INTERCEPT studies for MRD.”
Title: Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
Authors: Andrew J. Pellatt, Alisha Bent, Nicholas Hornstein, Christine Parseghian, Ryan Huey, Kanwal Raghav, Van Morris, Michael Overman, Pia Morelli, Jason Willis, Phat Le, John Paul Shen, Bryan Kee, Madhulika Eluri, Victoria Higbie, Kristin Alfaro-Munoz, Kathryn Aziz, Robert Kell, Ryan Sun, Scott Kopetz, Arvind Dasari
More posts featuring Scott Kopetz on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023